Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis' Exjade Receives Approval From The European Commission

Novartis AG (NVS: Quote) Friday said it has received approval from the European Commission for Exjade, an oral drug used to subside iron overload in patients undergoing chelation therapy for non-transfusion-dependent thalassemia, or NTDT, syndrome.

The approval is based on results from the placebo-controlled study of iron chelation in NTDT patients.

Thalassemia is a genetic disorder affecting red blood cell production, and thereby causing anemia. NTDT, unlike many other types of thalassemia, don't receive regular transfusion, subsequently resulting in a chronic iron overload.

Certain other health complication including liver fibrosis and cirrhosis, blood clots, bone disease, pulmonary hypertension, can also lead to higher iron concentration.

At least three quarters of a million people worldwide have NTDT syndromes, according to published studies.

In the pivotal study, named THALASSA, Exjade showed a significant dose-dependent decrease in concentration of iron-burden in the body as well as liver, compared to placebo. Meanwhile, the overall adverse event rate for Exjade was similar to the placebo arm.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving mostly higher over the course of the previous week, stocks showed a notable move back to the downside during trading on Monday. With the drop on the day, the Dow pulled back well off last Friday's record closing high. After reporting four consecutive monthly increases, the National Association of Realtors released a report on Monday showing an unexpected drop in U.S. existing home sales in the month of August. NAR said existing home sales fell 1.8 percent to a seasonally adjusted annual rate of 5.05 million in August. The European Central Bank remains ready to use additional unconventional tools to counter risks to the inflation outlook and to boost the euro area economy, ECB President Mario Draghi said on Monday. "The Governing Council remains fully determined to counter risks to the medium-term outlook for inflation," Draghi said in Brussels.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.